Effect of Xiaoyaosan on major depressive disorder.
Effect of Xiaoyaosan on major depressive disorder.
复制标题
逍遥散治疗重度抑郁症的疗效
DOI：
10.1186/s13020-015-0050-0
复制
发表时间：
2015
期刊：
影响因子：
4.9
通讯作者：
Sun XG
中科院分区：
文献类型：
--
作者：
Jing LL;Zhu XX;Lv ZP;Sun XG
本研究旨在评价逍遥散治疗抑郁症的疗效，并对逍遥散抗抑郁作用机制的研究进行综述。使用中国知识资源整合数据库（1998-2014）、VIP期刊整合平台（1989-2009）和PubMed（1950-2014）检索和收集与XYS和MDD相关的科学出版物。筛选“MDD”和“逍遥”的临床试验。纳入以消郁散原方治疗及与西药合用的文献，排除改良消郁散的文献。四名研究者独立阅读和筛选了所产生的出版物，评估了相关的科学结果和证据。由于样本量有限、盲法和随机化缺陷以及缺乏多中心临床试验，没有结论性结果支持XYS治疗MDD的疗效。在XYS影响的实验研究中，可能涉及5-羟色胺，下丘脑-垂体-肾上腺轴功能和神经炎症。XYS治疗MDD的有效性尚不确定。
This study aims to evaluate the efficacy of Xiaoyaosan (XYS) for treatment of major depressive disorder (MDD) and to review the studies on antidepressant mechanisms of XYS. The China Knowledge Resource Integrated Database (1998–2014), VIP Journal Integration Platform (1989–2009), and PubMed (1950–2014) were used to search for and collect scientific publications related to XYS and MDD. Clinical trials for “MDD” and “xiaoyao” were screened. Papers that used the original prescription of XYS for treatment and in combination with Western medicines were included, while papers describing modified XYS were excluded. Four investigators read and screened the resulting publications independently, evaluated the associated scientific results and evidence. There were no conclusive results to support the efficacy of XYS for treatment of MDD, owing to limited sample sizes, flaws in blinding and randomization, and lack of multi-centered clinical trials. Among the experimental studies on the effects of XYS possible involvement of 5-hydroxytryptamine, hypothalamic–pituitary–adrenal axis function, and neuroinflammation were possibly involved demonstrated. The effectiveness of XYS for treatment of MDD is uncertain.